Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $820.00 Price Target at Truist Financial

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective boosted by stock analysts at Truist Financial from $798.00 to $820.00 in a report released on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Truist Financial’s target price would suggest a potential upside of 0.76% from the company’s current price.

Several other equities research analysts also recently issued reports on REGN. Royal Bank Of Canada increased their price target on Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the stock a “sector perform” rating in a report on Wednesday, October 29th. UBS Group boosted their price objective on Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the company a “neutral” rating in a research report on Friday, November 7th. Citigroup lifted their price target on shares of Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. HSBC started coverage on shares of Regeneron Pharmaceuticals in a research report on Monday, November 24th. They set a “buy” rating and a $255.00 price objective for the company. Finally, BMO Capital Markets boosted their price objective on shares of Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the company an “outperform” rating in a research report on Thursday, December 4th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $791.05.

Regeneron Pharmaceuticals Trading Up 0.2%

Shares of REGN stock traded up $1.51 on Thursday, reaching $813.78. The company had a trading volume of 434,133 shares, compared to its average volume of 778,347. The stock has a market cap of $85.53 billion, a PE ratio of 19.49, a PEG ratio of 2.32 and a beta of 0.39. The company has a 50-day moving average of $732.29 and a 200-day moving average of $624.86. The company has a current ratio of 4.06, a quick ratio of 3.33 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a 12 month low of $476.49 and a 12 month high of $816.99.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. The firm had revenue of $3.75 billion during the quarter, compared to analysts’ expectations of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The business’s revenue for the quarter was up .9% on a year-over-year basis. During the same quarter in the previous year, the company earned $12.46 earnings per share. On average, equities analysts forecast that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Insider Activity at Regeneron Pharmaceuticals

In other news, VP Jason Pitofsky sold 431 shares of the company’s stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the sale, the vice president owned 4,233 shares of the company’s stock, valued at approximately $2,757,503.19. This represents a 9.24% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Christine A. Poon sold 6,500 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the transaction, the director directly owned 2,352 shares in the company, valued at $1,538,843.04. This trade represents a 73.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 7.02% of the stock is currently owned by insiders.

Institutional Trading of Regeneron Pharmaceuticals

Several large investors have recently bought and sold shares of the business. Salomon & Ludwin LLC bought a new stake in Regeneron Pharmaceuticals during the third quarter valued at $27,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $31,000. Board of the Pension Protection Fund acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $31,000. Caitlin John LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at about $34,000. Finally, Traub Capital Management LLC acquired a new stake in Regeneron Pharmaceuticals during the second quarter worth approximately $38,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Bank of America upgraded REGN to Buy from Underperform and raised its price objective to $860 (from $627), citing improving fundamentals across key products and multiple 2026 catalysts. Regeneron upgraded by Bank of America
• Positive Sentiment: Analyst sentiment has shifted noticeably — Benzinga highlights a move from Underperform to Buy at least at one major shop, signaling a potential change in the analyst consensus that can attract momentum investors. Regeneron just moved from underperform to buy
• Positive Sentiment: Coverage roundup: Benzinga’s analyst survey piece compiles views from 21 analysts, reinforcing that the recent rating upgrades and higher targets are influencing consensus expectations. 21 Analysts Assess Regeneron
• Positive Sentiment: Analyst upgrades combined with a drop in short interest may reduce selling pressure and improve the risk/reward profile for investors, according to coverage summarizing these flows. Analyst upgrades and short-interest drop
• Neutral Sentiment: Zacks highlights Regeneron’s history of beating estimates and argues the company has the attributes to deliver another earnings beat — a potential catalyst, but one that remains binary until results are posted. Will REGN beat estimates again?
• Neutral Sentiment: Several valuation/peer-compare stories (REGN vs ILMN, REGN vs AVIR) provide context for value investors but don’t introduce new company-specific catalysts; useful for relative-value decisions rather than immediate price moves. REGN vs ILMN comparison
• Neutral Sentiment: Additional head‑to‑head analyses (e.g., vs. Atea) are informational but not immediate catalysts. REGN vs AVIR analysis

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.